Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study

Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro and in vivo effects of everolimus in com...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Faggiano, A, Ramundo, V, Dicitore, A, Castiglioni, S, Borghi, M O, Severino, R, Ferolla, P, Crinò, L, Abbruzzese, A, Sperlongano, P, Caraglia, M, Ferone, D, Hofland, L, Colao, A, Vitale, G
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Publishing Ltd 2012
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3823224/
https://ncbi.nlm.nih.gov/pubmed/21883896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1582-4934.2011.01438.x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares